Ensysce Biosciences Inc
ENSC3.670USD
+1.800+96.26%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
4.98MMarket Cap
LossP/E TTM
More Details of Ensysce Biosciences Inc Company
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Company Info
Company codeENSC
Company nameEnsysce Biosciences Inc
IPO dateDec 01, 2017
Founded at2017
CEODr. Lynn D. Kirkpatrick, Ph.D.
Number of employees7
Security typeOrdinary Share
Fiscal year-endDec 01
Address7946 Ivanhoe Avenue, Suite 201
CityLA JOLLA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92037
Phone18582634196
Websitehttps://ensysce.com/
Company codeENSC
IPO dateDec 01, 2017
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David Carl Humphrey, CPA
Mr. David Carl Humphrey, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
10.00
--
Dr. Linda Pestano, Ph.D.
Dr. Linda Pestano, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Mr. Geoffrey Birkett
Mr. Geoffrey Birkett
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Steve R. Martin
Mr. Steve R. Martin
Independent Director
Independent Director
--
--
Bob G. Gower ,
Bob G. Gower ,
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey Millard, Ph.D.
Dr. Jeffrey Millard, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Curtis Rosebraugh, M.D.
Dr. Curtis Rosebraugh, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Carl Humphrey, CPA
Mr. David Carl Humphrey, CPA
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
10.00
--
Dr. Linda Pestano, Ph.D.
Dr. Linda Pestano, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. William H.C. Chang
Mr. William H.C. Chang
Independent Director
Independent Director
--
--
Ms. Lee M. Rauch
Ms. Lee M. Rauch
Independent Director
Independent Director
--
--
Mr. Geoffrey Birkett
Mr. Geoffrey Birkett
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Lynn D. Kirkpatrick, Ph.D.
Dr. Lynn D. Kirkpatrick, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Mar 2
Update time: Sun, Mar 2
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
5.27%
Adage Capital Management, L.P.
3.04%
Gower (Robert G)
0.49%
FNY Investment Advisers LLC
0.18%
Benton (Andrew K. J.D.)
0.08%
Other
90.93%
Shareholder Statistics
Shareholder
Proportion
Perceptive Advisors LLC
5.27%
Adage Capital Management, L.P.
3.04%
Gower (Robert G)
0.49%
FNY Investment Advisers LLC
0.18%
Benton (Andrew K. J.D.)
0.08%
Other
90.93%
Type
Shareholder
Proportion
Private Equity
5.27%
Hedge Fund
3.07%
Individual Investor
0.63%
Investment Advisor/Hedge Fund
0.18%
Investment Advisor
0.04%
Other
90.81%
Institutional Shareholding
Update time: Mon, Feb 24
Update time: Mon, Feb 24
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
35
151.14K
9.19%
-181.20K
2024Q4
41
152.48K
11.69%
-180.25K
2024Q3
42
173.09K
26.96%
+116.42K
2024Q2
41
44.94K
12.13%
-919.00
2024Q1
43
31.95K
18.34%
-413.00
2023Q4
44
15.51K
10.50%
-18.28K
2023Q3
49
27.39K
26.75%
-10.01K
2023Q2
49
42.64K
49.41%
+30.89K
2023Q1
50
17.95K
33.35%
+9.03K
2022Q4
49
6.68K
34.88%
+1.19K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
86.67K
5.27%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
50.00K
3.04%
+50.00K
--
Dec 31, 2024
Gower (Robert G)
8.13K
0.49%
--
--
Mar 07, 2025
FNY Investment Advisers LLC
3.00K
0.18%
+3.00K
--
Dec 31, 2024
Benton (Andrew K. J.D.)
1.33K
0.08%
--
--
Mar 07, 2025
Chang (William H C)
722.00
0.04%
-1.33K
-64.85%
Mar 07, 2025
UBS Financial Services, Inc.
595.00
0.04%
-6.92K
-92.08%
Dec 31, 2024
Tower Research Capital LLC
438.00
0.03%
+8.00
+1.86%
Dec 31, 2024
Kirkpatrick (D. Lynn)
107.00
0.01%
+1.00
+0.94%
Mar 07, 2025
BlackRock Institutional Trust Company, N.A.
64.00
0%
-1.00
-1.54%
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Date
Type
Ratio
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Dec 03, 2024
Merger
15<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Mar 30, 2023
Merger
12<1
Oct 27, 2022
Merger
20<1
Oct 27, 2022
Merger
20<1
View more